Sectors & IndustriesHealthcare

Best Healthcare Stocks to Buy Now (2025)

Top healthcare stocks in 2025 ranked by overall Due Diligence Score. See the best healthcare stocks to buy now, according to analyst forecasts for the healthcare sector.

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best healthcare stocks to buy right now are:

Pediatrix Medical Group (NYSE:MD) is the #1 top healthcare stock out of 1097 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Pediatrix Medical Group (NYSE:MD) is: Value: A, Growth: B, Momentum: B, Sentiment: A, Safety: B, Financials: B, and AI: C.

Pediatrix Medical Group (NYSE:MD) has a Due Diligence Score of 36, which is 10 points higher than the healthcare sector average of 26. It passed 11 out of 33 due diligence checks and has average fundamentals. Pediatrix Medical Group has seen its stock return 58.67% over the past year, overperforming other healthcare stocks by 88 percentage points.

Pediatrix Medical Group has an average 1 year price target of $21.33, a downside of -7.09% from Pediatrix Medical Group's current stock price of $22.96.

Pediatrix Medical Group stock has a consensus Hold recommendation according to Wall Street analysts. Of the 3 analysts covering Pediatrix Medical Group, 0% have issued a Strong Buy rating, 0% have issued a Buy, 100% have issued a Hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Collegium Pharmaceutical (NASDAQ:COLL) is the #2 top healthcare stock out of 1097 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Collegium Pharmaceutical (NASDAQ:COLL) is: Value: A, Growth: B, Momentum: C, Sentiment: B, Safety: C, Financials: B, and AI: B.

Collegium Pharmaceutical (NASDAQ:COLL) has a Due Diligence Score of 46, which is 20 points higher than the healthcare sector average of 26. It passed 16 out of 33 due diligence checks and has strong fundamentals. Collegium Pharmaceutical has seen its stock return 55.17% over the past year, overperforming other healthcare stocks by 85 percentage points.

Collegium Pharmaceutical has an average 1 year price target of $46.67, an upside of 2.93% from Collegium Pharmaceutical's current stock price of $45.34.

Collegium Pharmaceutical stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 3 analysts covering Collegium Pharmaceutical, 33.33% have issued a Strong Buy rating, 66.67% have issued a Buy, 0% have issued a Hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Indivior (NASDAQ:INDV) is the #3 top healthcare stock out of 1097 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Indivior (NASDAQ:INDV) is: Value: B, Growth: B, Momentum: B, Sentiment: A, Safety: B, Financials: B, and AI: C.

Indivior (NASDAQ:INDV) has a Due Diligence Score of 23, which is -3 points lower than the healthcare sector average of 26. Although this number is below the industry average, our proven quant model rates INDV as a "A".It passed 7 out of 33 due diligence checks and has weak fundamentals. Indivior has seen its stock return 222.28% over the past year, overperforming other healthcare stocks by 252 percentage points.

Indivior has an average 1 year price target of $32.50, an upside of 0.74% from Indivior's current stock price of $32.26.

Indivior stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 4 analysts covering Indivior, 50% have issued a Strong Buy rating, 50% have issued a Buy, 0% have issued a Hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Out of 71 healthcare stocks that have issued dividends in the past year, the 3 healthcare stocks with the highest dividend yields are:

Select Medical Holdings (NYSE:SEM) has an annual dividend yield of 13.89%, which is 12 percentage points higher than the healthcare sector average of 2.09%. Select Medical Holdings's dividend payout is not stable, having dropped more than 10% one times in the last 10 years. Select Medical Holdings's dividend has not shown consistent growth over the last 10 years.

Select Medical Holdings's dividend payout ratio of 36% indicates that its high dividend yield is sustainable for the long-term.

Dominari Holdings (NASDAQ:DOMH) has an annual dividend yield of 11.2%, which is 9 percentage points higher than the healthcare sector average of 2.09%.

Dominari Holdings's dividend payout ratio of 8.4% indicates that its high dividend yield is sustainable for the long-term.

Spok Holdings (NASDAQ:SPOK) has an annual dividend yield of 9.7%, which is 8 percentage points higher than the healthcare sector average of 2.09%. Spok Holdings's dividend payout is not stable, having dropped more than 10% two times in the last 10 years. Spok Holdings's dividend has shown consistent growth over the last 10 years.

Spok Holdings's dividend payout ratio of 154.3% indicates that its high dividend yield might not be sustainable for the long-term.

Healthcare stocks were up 0.41% in the last day, and down -0.2% over the last week. Vanda Pharmaceuticals was the among the top gainers in the healthcare sector, gaining 21.59% yesterday.

Vanda Pharmaceuticals shares are trading higher after the company reported that tradipitant lowered GLP 1 induced nausea and vomiting in adult participants.

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued healthcare stocks right now are:

Auna Sa (NYSE:AUNA) is the most undervalued healthcare stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Auna Sa has a valuation score of 57, which is 40 points higher than the healthcare sector average of 17. It passed 4 out of 7 valuation due diligence checks.

Auna Sa's stock has dropped -27.34% in the past year. It has overperformed other stocks in the healthcare sector by 2 percentage points.

Harmony Biosciences Holdings (NASDAQ:HRMY) is the second most undervalued healthcare stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Harmony Biosciences Holdings has a valuation score of 71, which is 54 points higher than the healthcare sector average of 17. It passed 5 out of 7 valuation due diligence checks.

Harmony Biosciences Holdings's stock has gained 2.78% in the past year. It has overperformed other stocks in the healthcare sector by 32 percentage points.

Organon & Co (NYSE:OGN) is the third most undervalued healthcare stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Organon & Co has a valuation score of 71, which is 54 points higher than the healthcare sector average of 17. It passed 5 out of 7 valuation due diligence checks.

Organon & Co's stock has dropped -48.94% in the past year. It has underperformed other stocks in the healthcare sector by -20 percentage points.

54.28% of healthcare stocks rated by analysts are a strong buy right now. On average, analysts expect healthcare stocks to rise by 28.29% over the next year.

8.42% of healthcare stocks have a Zen Rating of A (Strong Buy), 12.16% of healthcare stocks are rated B (Buy), 46.43% are rated C (Hold), 23.63% are rated D (Sell), and 9.36% are rated F (Strong Sell).